NCT04174599 2025-04-20
Study to Compare the Efficacy and Safety of F-627 and GRAN®
EVIVE Biotechnology
Phase 3 Completed
Clinical Trials
20 trialsNCT02527746 2024-02-23
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 1 Completed
NCT03252431 2023-07-03
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 3 Completed
NCT01724866 2022-04-15
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT02643420 2022-03-02
ADVANCE
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT02953340 2022-03-02
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT02190721 2021-12-10
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT02872103 2021-05-05
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 3 Completed
NCT01648322 2018-10-03
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 2 Completed
NCT01619423 2018-07-06
PLIANT
Egetis Therapeutics
Phase 1/2 Completed
NCT00911170 2017-12-29
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
Phase 3 Completed
NCT00771810 2017-11-13
Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
Tarix Pharmaceuticals
Phase 2 Completed
NCT01516736 2017-08-30
PROTECT2
Sandoz
Phase 3 Completed
NCT01735175 2017-08-07
PROTECT-1
Sandoz
Phase 3 Completed
NCT00686543 2017-04-07
Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT01569087 2016-12-05
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
Biocad
Phase 2 Completed
NCT02104830 2016-10-24
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
Biocad
Phase 3 Completed
NCT01519700 2015-05-06
PIONEER
Sandoz
Phase 3 Completed
NCT01021683 2013-08-12
The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants
Janssen Korea, Ltd., Korea
Completed
NCT00529282 2012-08-01
A Study of Ceftobiprole in Patients With Fever and Neutropenia.
Basilea Pharmaceutica
Phase 3 Terminated